Charles F Haines1, John A Fleishman, Baligh R Yehia, Stephen A Berry, Richard D Moore, Laura P Bamford, Kelly A Gebo. 1. *Division of Infectious Diseases, Department of Medicine, The Johns Hopkins of Medicine, Baltimore, MD; †Agency for Healthcare Research and Quality (AHRQ); ‡Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and §Jonathan Lax Treatment Center, Philadelphia, PA.
Abstract
BACKGROUND: Earlier HIV diagnosis and engagement in care improve outcomes and is cost effective, as a result, in 2006, the Centers for Disease Control and Prevention (CDC) revised the HIV-screening guidelines. We sought to determine whether the CD4 count (CD4) at presentation, a surrogate for time to presentation, increased during the study period. Our a priori hypothesis was that the CD4 at presentation increased during the study period, particularly after the CDC guideline revision. METHODS: We performed a retrospective cohort study and analyzed data from the HIV Research Network, a consortium of 18 US clinics caring for HIV-infected patients. HIV-infected adults (≥18 years old) newly presenting for care between 2003 and 2011 were included in this study. Multivariable linear regression examined associations with CD4 at enrollment. Calendar year was modeled as a linear spline with a change in slope at 2008, allowing determination of the mean change in CD4 per year during 2003-2007 and 2008-2011. RESULTS: Over 13,543 newly presenting subjects enrolled from 2003 to 2011. Median CD4 at enrollment rose from 285 to 317 cells per cubic millimeter between 2003-2007 and 2008-2011 (P < 0.001). After adjusting for age, race/ethnicity, gender, HIV risk factor, and clinic site, the mean increase in the CD4 count at presentation per year was 13.3 cells per cubic millimeter per year (95% confidence interval 6.4 to 20.1 cells per cubic millimeter per year) greater during 2008-2011 than during 2003-2007. CONCLUSIONS: We demonstrate a small, but statistically significant, increase in CD4 at presentation after the CDC guideline revision. More efforts are needed to decrease time to presentation to HIV care.
BACKGROUND: Earlier HIV diagnosis and engagement in care improve outcomes and is cost effective, as a result, in 2006, the Centers for Disease Control and Prevention (CDC) revised the HIV-screening guidelines. We sought to determine whether the CD4 count (CD4) at presentation, a surrogate for time to presentation, increased during the study period. Our a priori hypothesis was that the CD4 at presentation increased during the study period, particularly after the CDC guideline revision. METHODS: We performed a retrospective cohort study and analyzed data from the HIV Research Network, a consortium of 18 US clinics caring for HIV-infectedpatients. HIV-infected adults (≥18 years old) newly presenting for care between 2003 and 2011 were included in this study. Multivariable linear regression examined associations with CD4 at enrollment. Calendar year was modeled as a linear spline with a change in slope at 2008, allowing determination of the mean change in CD4 per year during 2003-2007 and 2008-2011. RESULTS: Over 13,543 newly presenting subjects enrolled from 2003 to 2011. Median CD4 at enrollment rose from 285 to 317 cells per cubic millimeter between 2003-2007 and 2008-2011 (P < 0.001). After adjusting for age, race/ethnicity, gender, HIV risk factor, and clinic site, the mean increase in the CD4 count at presentation per year was 13.3 cells per cubic millimeter per year (95% confidence interval 6.4 to 20.1 cells per cubic millimeter per year) greater during 2008-2011 than during 2003-2007. CONCLUSIONS: We demonstrate a small, but statistically significant, increase in CD4 at presentation after the CDC guideline revision. More efforts are needed to decrease time to presentation to HIV care.
Authors: Kelly A Gebo; John A Fleishman; Richard Conviser; Erin D Reilly; P Todd Korthuis; Richard D Moore; James Hellinger; Philip Keiser; Haya R Rubin; Lawrence Crane; Fred J Hellinger; W Christopher Mathews Journal: J Acquir Immune Defic Syndr Date: 2005-01-01 Impact factor: 3.731
Authors: Keri N Althoff; Stephen J Gange; Marina B Klein; John T Brooks; Robert S Hogg; Ronald J Bosch; Michael A Horberg; Michael S Saag; Mari M Kitahata; Amy C Justice; Kelly A Gebo; Joseph J Eron; Sean B Rourke; M John Gill; Benigno Rodriguez; Timothy R Sterling; Liviana M Calzavara; Steven G Deeks; Jeffrey N Martin; Anita R Rachlis; Sonia Napravnik; Lisa P Jacobson; Gregory D Kirk; Ann C Collier; Constance A Benson; Michael J Silverberg; Margot Kushel; James J Goedert; Rosemary G McKaig; Stephen E Van Rompaey; Jinbing Zhang; Richard D Moore Journal: Clin Infect Dis Date: 2010-06-01 Impact factor: 9.079
Authors: Rochelle P Walensky; Milton C Weinstein; April D Kimmel; George R Seage; Elena Losina; Paul E Sax; Hong Zhang; Heather E Smith; Kenneth A Freedberg; A David Paltiel Journal: Am J Med Date: 2005-03 Impact factor: 4.965
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Viktor Müller; Viktor von Wyl; Sabine Yerly; Jürg Böni; Thomas Klimkait; Philippe Bürgisser; Bruno Ledergerber; Huldrych F Günthard; Sebastian Bonhoeffer Journal: AIDS Date: 2009-06-19 Impact factor: 4.177
Authors: Nikos Pantazis; Charles Morrison; Pauli N Amornkul; Charlotte Lewden; Robert A Salata; Albert Minga; Tsungai Chipato; Harold Jaffe; Shabir Lakhi; Etienne Karita; Kholoud Porter; Laurence Meyer; Giota Touloumi Journal: PLoS One Date: 2012-03-06 Impact factor: 3.240
Authors: Brettania L W Lopes; Joseph J Eron; Michael J Mugavero; William C Miller; Sonia Napravnik Journal: J Acquir Immune Defic Syndr Date: 2017-10-01 Impact factor: 3.731